1[1]Brandes AA, Ermani M, Basso U, et al. Temozolomide as a secondline systemic regimen in recurrent high-grade glioma:a phaseⅡstudy Ann Oncol,2001,12:255-257. 被引量：1
2[2]Stupp R,Dietrich PY,Ostermann Kraljevic S,et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plustemozolomide followed by adjuvanttemozolomide.J Clin Oncol,2002,20:1375-1382. 被引量：1
3[3]Yung WK,Albright RE,Olson J,et al. A phaseⅡstudy oftemozolomide vs.procarbazine in patients with glioblastoma multiforme at first relapse.Br J Cancer,2000,83:588-593. 被引量：1
4[6]Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol, 2001, 19:2449-2455. 被引量：1
5[7]Amstrong T, Hancock C. Temodar offers promise for treating astrocytomas. Clin J Oncol Nurs, 2000, 4:159-160. 被引量：1
6[8]Antonadou D, Paraskevaidis M, Sarris G, et al. Phase Ⅱ randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol, 2002, 20:3644-3650. 被引量：1
8[10]Brada M, Judson I, Beale P, et al. Phase Ⅰ dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer, 1999, 81:1022-1030. 被引量：1
9[11]Yung WK. Future direction for temozolomide therapy. Semin Oncol,2001, 28:43-46. 被引量：1
10[12]Macdonald DR. Temozolomide for recurrent high-grade glioma.Semin Oncol, 2001, 28:3-12. 被引量：1
